Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab. (8th June 2018)

• Record Type: Journal Article
• Authors: Facchinetti, Francesco; Veneziani, Michele; Buti, Sebastiano; Gelsomino, Francesco; Squadrilli, Anna; Bordi, Paola; Bersanelli, Melissa; Cosenza, Agnese; Ferri, Leonarda; Rapacchi, Elena; Mazzaschi, Giulia; Leonardi, Francesco; Quaini, Federico; Ardizzoni, Andrea; Missale, Gabriele; Tiseo, Marcello
• Is Part Of: Immunotherapy. Volume 10:Number 8(2018)
• Page Start: 681
• Page End: 694
• Publication Date: 2018-06-08
• Subjects: anticancer immunotherapy -- hematological parameters -- immune checkpoint inhibitors -- nivolumab -- non-small-cell lung cancer -- prognostic factors; Immunotherapy -- Periodicals; 615.37
• DOI: 10.2217/imt-2017-0175
• Languages: English
• ISSNs: 1750-743X

Abstract

Aim: This prospective study aimed to envisage the putative prognostic significance of clinical and hematologic parameters in advanced non-small-cell lung cancer patients treated with nivolumab.Materials & methods: Correlations of several parameters with disease control and survival outcomes were provided.Results: A total of 54 patients were included. An ECOG performance status 0–1, the lack of liver and bone metastases and a timeframe from the last systemic treatment ≥4 months correlated with better disease control. The same was observed for baseline low levels of white blood cells and neutrophils, for high levels of NK cells and a neutrophil/lymphocyte ratio <4. The mentioned parameters were also associated with longer overall survival.Conclusion: Nivolumab efficacy in non-small-cell lung cancer patients is influenced by clinicopathological parameters and specific leucocyte subsets.